Genetic Technologies Ltd.
GENE
GENE was delisted on the 16th of October, 2024.
10 hedge funds and large institutions have $274K invested in Genetic Technologies Ltd. in 2014 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 0 closing their positions.
448% more capital invested
Capital invested by funds: $50K → $274K (+$224K)
100% more funds holding
Funds holding: 5 → 10 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$74.2K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$63.5K |
| 3 |
Morgan Stanley
New York
|
+$43.4K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
+$23.8K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$17.9K |
Top Sellers
GENE Hedge Fund Activity: Q1 2014 in Review
10 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Genetic Technologies Ltd. (GENE) for Q1 2014, worth a combined $274K — up 448% from $50K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new GENE positions and 0 closed out — a net gain of 5 holders — while 4 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $74.2K.
- 10 institutional investors held Genetic Technologies Ltd. (GENE) as of Q1 2014, up from 5 in Q4 2013.
- Funds reported $274K of Genetic Technologies Ltd. stock for Q1 2014, up 448% quarter-over-quarter.
- 5 funds opened new Genetic Technologies Ltd. positions in Q1 2014 and 0 closed out, a net change of +5 holders.
- The largest Genetic Technologies Ltd. buyer in Q1 2014 was Citadel Advisors, an estimated $74.2K added.
Based on aggregated 13F filings for Q1 2014.